statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ( Oculis ), a global biopharmaceutical company purposefully driven to save sight and improve eye...

Oculis to Participate at Upcoming April Investor Conferences

Oculis Holding AG (NASDAQ:OCS  Free Report)  Stock analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Oculis in a research report issued to clients and...

Oculis Holding AG (NASDAQ:OCS) Expected to Post Q1 2024 Earnings of ($0.40) Per Share

Oculis Holding AG (NASDAQ:OCS  Free Report)  Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Oculis in a research note...

Leerink Partnrs Comments on Oculis Holding AG's Q1 2024 Earnings (NASDAQ:OCS)

Shares of Oculis Holding AG (NASDAQ:OCS  Get Free Report) have received an average rating of Buy from the nine research firms that are currently covering the stock, Marketbeat...

Brokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $33.43

A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for...

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Oculis Holding AG (NASDAQ:OCS  Get Free Report) has been assigned a consensus recommendation of Buy from the nine brokerages that are covering the company, Marketbeat Ratings...

Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $33.43

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3...

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Wolverine Asset Management LLC acquired a new stake in Oculis Holding AG (NASDAQ:OCS  Free Report) during the third quarter, according to its most recent disclosure with the Securities and...

7,021 Shares in Oculis Holding AG (NASDAQ:OCS) Purchased by Wolverine Asset Management LLC

ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ( Oculis ), a global biopharmaceutical company purposefully driven to save sight and improve eye care...

Oculis to Present at Upcoming February Investor Conferences

Shares of Oculis Holding AG (NASDAQ:OCS  Get Free Report) have been given a consensus recommendation of Buy by the nine ratings firms that are covering the stock, MarketBeat...

Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $33.43

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Volume	91,813.00
52-Wk High	$14.50
52-Wk Low	$9.05

OCS Oculis Holding AG

About

Feed

News

Sentiment

Fundamentals